Literature DB >> 16880491

Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report.

U D Parthasarathi1, T Harrower, M Tempest, J R Hodges, C Walsh, P J McKenna, P C Fletcher.   

Abstract

Voltage-gated potassium channel antibody encephalopathy, a rare cause of limbic encephalopathy, typically presents with memory impairment and seizures. Psychiatric symptoms have not been emphasised in the literature. Here we describe a 58-year-old man who presented with panic attacks and psychogenic non-epileptic seizures and, later on, developed delusions and hallucinations and then confusion. He was found to have antibodies to voltage-gated potassium channels. Treatment with immuno-modulatory therapy resulted in almost complete recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880491      PMCID: PMC3838945          DOI: 10.1192/bjp.bp.105.012864

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  9 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Neurological syndromes which can be mistaken for psychiatric conditions.

Authors:  C Butler; A Z J Zeman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates.

Authors:  Beau M Ances; Roberta Vitaliani; Robert A Taylor; David S Liebeskind; Alfredo Voloschin; David J Houghton; Steven L Galetta; Marc Dichter; Abass Alavi; Myrna R Rosenfeld; Josep Dalmau
Journal:  Brain       Date:  2005-05-11       Impact factor: 13.501

4.  Potassium channel antibodies in two patients with reversible limbic encephalitis.

Authors:  C Buckley; J Oger; L Clover; E Tüzün; K Carpenter; M Jackson; A Vincent
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 5.  Frontal lobe epilepsy.

Authors:  Christoph Kellinghaus; Hans O Lüders
Journal:  Epileptic Disord       Date:  2004-12       Impact factor: 1.819

6.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

7.  Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody.

Authors:  M J Thieben; V A Lennon; B F Boeve; A J Aksamit; M Keegan; S Vernino
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

8.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.

Authors:  Angela Vincent; Camilla Buckley; Jonathan M Schott; Ian Baker; Bonnie-Kate Dewar; Niels Detert; Linda Clover; Abigail Parkinson; Christian G Bien; Salah Omer; Bethan Lang; Martin N Rossor; Jackie Palace
Journal:  Brain       Date:  2004-02-11       Impact factor: 13.501

9.  Voltage-gated potassium channel antibodies in limbic encephalitis.

Authors:  Patricia Pozo-Rosich; Linda Clover; Albert Saiz; Angela Vincent; Francesc Graus
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

  9 in total
  12 in total

Review 1.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

Review 2.  The evaluation of rapidly progressive dementia.

Authors:  Michael Henry Rosenbloom; Alireza Atri
Journal:  Neurologist       Date:  2011-03       Impact factor: 1.398

Review 3.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

4.  ST3GAL3 mutations impair the development of higher cognitive functions.

Authors:  Hao Hu; Katinka Eggers; Wei Chen; Masoud Garshasbi; M Mahdi Motazacker; Klaus Wrogemann; Kimia Kahrizi; Andreas Tzschach; Masoumeh Hosseini; Ideh Bahman; Tim Hucho; Martina Mühlenhoff; Rita Gerardy-Schahn; Hossein Najmabadi; H Hilger Ropers; Andreas W Kuss
Journal:  Am J Hum Genet       Date:  2011-09-09       Impact factor: 11.025

Review 5.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

Review 6.  Neuropsychological Evaluations in Limbic Encephalitis.

Authors:  Juri-Alexander Witt; Christoph Helmstaedter
Journal:  Brain Sci       Date:  2021-04-29

7.  Disease-relevant autoantibodies in first episode schizophrenia.

Authors:  Michael S Zandi; Sarosh R Irani; Bethan Lang; Patrick Waters; Peter B Jones; Peter McKenna; Alasdair J Coles; Angela Vincent; Belinda R Lennox
Journal:  J Neurol       Date:  2010-10-26       Impact factor: 4.849

Review 8.  From drugs to deprivation: a Bayesian framework for understanding models of psychosis.

Authors:  P R Corlett; C D Frith; P C Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2009-05-28       Impact factor: 4.530

Review 9.  Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies.

Authors:  G M Khandaker; J Zimbron; G Lewis; P B Jones
Journal:  Psychol Med       Date:  2012-04-16       Impact factor: 7.723

10.  Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features.

Authors:  Ko Tsutsui; Takashi Kanbayashi; Keiko Tanaka; Shuken Boku; Wakako Ito; Jun Tokunaga; Akane Mori; Yasuo Hishikawa; Tetsuo Shimizu; Seiji Nishino
Journal:  BMC Psychiatry       Date:  2012-05-08       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.